Tourette Syndrome: a literary review of the treatments available for the alleviation of tics
DOI:
https://doi.org/10.33448/rsd-v12i1.39307Keywords:
Tourette Syndrome; Treatment; Drug therapy; Reduction of tics.Abstract
Tourette Syndrome (TS) is an early childhood disorder, marked by the presence of multiple motor tics and at least one vocal tic, which, sometimes, can be accompanied by psychiatric comorbidities, Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive-Compulsive Disorder (OCD). The objective was to carry out an analysis of studies that refer to the treatments currently available for TS, analyzing the priority of recommendation, its effectiveness, its possible harm and its contribution to improving the quality of life of patients. This is a literature review about the main treatments available for TS. The descriptors “tourette syndrome”, “treatments”, “drug therapy” and “obsessive compulsive disorder” were crossed in the Virtual Health Library (VHL), Scientific Electronic Library Online (SciELO), National Library of Medicine (PubMed), EbscoHost and Google Scholar. It has been found that initial treatment for Tourette's Syndrome should be based on Supportive Therapy along with the first line of treatment, with behavioral intervention. If there are no results in reducing tics, the second line of treatment, pharmacological intervention, should be implemented. On the other hand, the third line of treatment, is recommended in about 5% of cases of TS, cases in which previous treatments, like non-drug therapies and drugs, did not have the desired effect. Several lines of treatment act to alleviate the symptoms, thus, the treatment can be characterized as being multifaceted and individualized, as it needs to be developed taking into account the individual's specifications and the expressions of the disease on him.
References
Andrén, P., et al. (2021). European clinical guidelines for Tourette Syndrome and other tics disorders- version 2.0. Part II: psychological interventions. European Child & Adolescent Psychiatry, 31, 403-423.
Anis, S., et al. (2022). Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. Hindawi, Behavioural Neurology, 5141773.
Badenoch, J., & Cavanna, A. E. (2020). Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders. Neurological Sciences, 41, 1923-1926.
Billnitzer, A., & Jankovic, J. (2020). Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. The American Society for Experimental NeuroTherapeutics, 17, 1681-1693.
Dantas, D. M., & Porto, R. M. (2022). Desafios no Tratamento do Indivíduo Portador da Síndrome de Tourette: Uma Revisão Integrativa. Contemporânea –Revista de Ética e Filosofia Política, 2 (3), 228-245.
Estrela, C. (2018). Metodologia Científica: Ciência, Ensino, Pesquisa. Editora Artes Médicas.
Ferraz, K. F., et al. (2019). Aripiprazol na Sindrome de Tourette em Adultos: Relato de Caso e Revisão Narrativa. Revista Debates in Psychiatry, 9 (2), 61.
Frey, J., & Malaty, I. A. (2022). Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature. Current Neurology and Neuroscience Reports, 22, 123-142.
Hsu, C. J., Wong, L. C., & Lee, W. T. (2021). Immunological Dysfunction in Tourette Syndrome and Related Disorders. Int. J. Mol. Sci., 22, 853.
Katz, T. M., et al. (2022). Tourettic OCD: Current understanding and treatment challenges of a unique endophenotype. Front Psychiatry, Sec Child and Adolescent Psychiatry, 929526.
Liu, A., et al. (2022). Improved depressive symptoms in patients with refractory Gilles de la Tourette Syndrome after deep brain stimulation of posteroventral globus pallidus interna. Brain and Behavior published by Wiley Periodicals LLC, 12 (7).
Martino, D., et al. (2021). The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection. American Academy of Neurology, 96, 664-676.
Mendonça, M. J. M., & Mendes, L. P. B. (2022). Síndrome de Tourette na infância: uma abordagem farmacológica na resolução de tiques. Brazilian Journal of Health Review, 5 (1), 1647-1653.
Milosev, L. M., et al. (2019). Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis and Cannabinoid Research, 4 (4).
Muller-Vahl, K. R., et al. (2021). European clinical guidelines for Tourette Syndrome and other tics disorders: summary statment. European Child & Adolescent Psychiatry, 31, 377-382.
Nomura, Y. (2021). Pharmacological Therapy for Tourette Syndrome: What Medicine can do and cannot do. Science Direct Biomedical Journal, 45, 229-239.
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., & & McKenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. bmj, 372.
Pringheim, T., et al. (2019). Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. American Academy of Neurology, 92, 907-915.
Quezada, J., & Coffman, K. A. (2018). Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome. CNS Drugs, 32, 33-45.
Sjezco, N., et al. (2021). European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation. European Child & Adolescent Psychiatry, 31 (3), 443-461.
Souza, M. T. d., Silva, M. D. d., & Carvalho, R. d. (2010). Integrative review: what is it? How to do it? Einstein (São Paulo), 8(1), 102–106.
Wang, X., et al. (2022). Stereotactic Surgery for Treating Intractable Tourette Syndrome: a Single-Center Pilot Study. Brain Sci, 12, 838.
Xu, W., et al. (2020). Deep brain stimulation for Tourette’s syndrome. Translational Neurodegeneration, 9 (4).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Luísa Diniz Napoleão; Bethania Cristhine de Araujo; Iris Isabela da Silva Medeiros Guimarães; Natalia de Fátima Gançalves Amâncio
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
